NASDAQ: CCCC · Life Sciences · 4 alerts · CIK 1662579
Share price
$2.65Close, Nov 16
Market cap
$348M
Shares outstanding
131.32MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All C4 Therapeutics, Inc. filings on SEC EDGAR ↗
C4 Therapeutics CFO Kendra Adams Sells $122K of Stock
Kendra Adams, CFO, sold 45,173 shares of C4 Therapeutics, Inc. at $2.71 a share, worth $122K in total on Nov 12, 2026. Shares held after the trade: 337,150 (-11.8%).
C4 Therapeutics is a clinical-stage biopharmaceutical company focused on its TORPEDO platform and protein degrader candidates. As of October 30, 2026, the company had 131,317,488 shares of common stock outstanding and continues to incur significant losses to fund its research and development programs.
C4 Therapeutics reported financial results for the third quarter of 2026, highlighting clinical progress for its lead candidate cemsidomide. The company remains on track to complete enrollment for the Phase 2 MOMENTUM trial in Q1 2027 and expects initial data from multiple combination cohorts in mid-to-late 2027.
“Throughout the year, we have continued to build evidence supporting cemsidomide’s potential as a backbone therapy across the multiple myeloma treatment landscape while advancing our clinical development plan to evaluate cemsidomide in late and earlier lines of therapy.”
Andrew Hirsch, president and chief executive officer of C4 Therapeutics
“With data expected from these trials in 2027, we believe next year will be pivotal in establishing cemsidomide’s therapeutic profile and its potential to address the significant unmet need of patients with multiple myeloma across an evolving standard of care.”
Andrew Hirsch, president and chief executive officer of C4 Therapeutics